Clinica Baviera
Research Clinica Baviera (CBAV) on Bullrun: valuation model: 9.9% undervalued, market cap EUR 884.22M, P/E 21.0, dividend yield 2.8%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCBAV
- ExchangeMC
- CountrySpain
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyEUR
- Valuation signal9.9% undervalued
- Market capEUR 884.22M
- P/E21.0
- Dividend yield2.8%
- Financial periodFY2024
- RevenueEUR 262.65M
- Revenue growth16.8%
- Net incomeEUR 41.14M
- Free cash flowEUR 36.00M
Valuation Snapshot
Bullrun's latest valuation model marks Clinica Baviera as 9.9% undervalued; latest market cap is EUR 884.22M; P/E is 21.0; dividend yield is 2.8%.
About Clinica Baviera
Clínica Baviera, S.A., a medical company, provides ophthalmologic medicine services in Spain, Germany, and rest of Europe. The company offers refractive, presbyopia, and cataract surgeries; and oculoplastia, corneal disease, dry eye, strabismus, pediatric ophthalmology, glaucoma, neuro-ophthalmological, disorders, and blepharoplasty treatments. It also provides external and internal consultations, surgery treatments, and rehabilitation services. The company was formerly known as Clínica Oftalmológica Baviera, S.L.
Frequently asked questions
Is Clinica Baviera overvalued or undervalued?
Bullrun's valuation model currently marks Clinica Baviera as 9.9% undervalued.
What is Clinica Baviera's market cap?
Clinica Baviera's market capitalization is EUR 884.22M.
What is Clinica Baviera's P/E ratio?
Clinica Baviera's price-to-earnings (P/E) ratio is 21.0.
Does Clinica Baviera pay a dividend?
Clinica Baviera has a dividend yield of 2.8%.
What does Clinica Baviera do?
Clínica Baviera, S.A., a medical company, provides ophthalmologic medicine services in Spain, Germany, and rest of Europe. The company offers refractive, presbyopia, and cataract surgeries;